SCHEMBL684348

SCHEMBL684348

Cn1c(=O)c2c(ncn2CCCN2CCCN(Cc3ccc(Cl)c(Cl)c3)CC2)n(C)c1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.69
LMNA P02545 2/20 0.69
HTT P42858 2/20 0.69
UBE2N P61088 2/20 0.69
MAOB P27338 6/20 0.55
ADORA2A P29274 2/20 0.55
ADORA1 P30542 1/20 0.55
HTR7 P34969 1/20 0.54
HTR6 P50406 1/20 0.54
HTR1A P08908 2/20 0.54
CHRM1 P11229 2/20 0.54
DRD2 P14416 2/20 0.54
ADRA1D P25100 2/20 0.54
ADRA1A P35348 2/20 0.54
ADRA1B P35368 2/20 0.54
MAPK1 P28482 1/20 0.53
ADORA2B P29275 4/20 0.52
GLA P06280 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10896818 0.99 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHTTUBE2NMAOB
Hydrochloric Acid SCHEMBL10899529 0.99 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHTTUBE2NMAOB
SCHEMBL684347 0.90 LMNA (0.67) SMN1; SMN2LMNAHTTUBE2NMAOB
SCHEMBL10896398 0.88 LMNA (0.67) SMN1; SMN2LMNAHTTUBE2NMAOB
SCHEMBL684342 0.88 SMN1; SMN2 (0.70) SMN1; SMN2LMNAHTTUBE2NMAOB
SCHEMBL684013 0.87 HTR1A (0.69) SMN1; SMN2LMNAHTTUBE2NHTR7
SCHEMBL683634 0.87 HTR7 (0.67) SMN1; SMN2LMNAHTTUBE2NADORA2A
SCHEMBL10896463 0.86 RXFP1 (0.60) SMN1; SMN2LMNAHTTUBE2NHTR7
SCHEMBL683590 0.85 SMN1; SMN2 (0.64) SMN1; SMN2LMNAHTTUBE2NMAOB
SCHEMBL10896210 0.85 HTR1A (0.67) SMN1; SMN2LMNAHTTUBE2NHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-4599414-A ANTHISTAMINES, VASODILATORS EISAI CO., LTD. (JP) 1986-07-08 US disclosed
EP-0023350-A1 Theophylline derivatives, a process for the preparation of the same and a therapeutical composition Eisai Co., Ltd. (JP) 1981-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF SMN1; SMN2 907/4885LMNA 2155/4885HTT 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.